SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Medical Oncology Consultation — Sun Yat-sen — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Sun Yat-sen |
|---|
| Date of birth | 1866-11-12 |
|---|
| Identifiers | MRN HR-ET016-SYN-TD; SSN (made up) 000-16-4183 |
|---|
| Document date | 1924-05-18 |
|---|
| Author | Raymond Choi, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Referral
A solid 6.8 cm mass in liver segments IV and V, inseparable from a gallbladder containing stones, in a 57-year-old man with three months of right upper abdominal aching, early fullness and 4 kg weight loss. He trained and briefly practiced as a physician. Multiphase CT, tumor markers and hepatitis serology are under way. Please establish the diagnosis, stage the disease, take him to the tumor board, and advise on treatment. [S]
Urgency: Within two weeks, with the CT and any biopsy result. [S]
Questions for the consultant:
- Is this a primary liver cancer, a gallbladder or other biliary cancer, or a metastasis, and what tissue diagnosis is needed?
- What further staging is needed, and is the tumor resectable?
- How do his liver function and hepatitis B and C status affect the options?
- What treatment do you advise, and how should it be planned with the multidisciplinary tumor board?
- When should specialist palliative care join, and how should results be shared with a patient who is himself a physician?
History of Present Illness
Mr. Sun, a 57-year-old political leader who trained and briefly practiced in medicine, is seen at the request of Dr. Huang two weeks after presenting with three months of right upper abdominal aching, early fullness and 4 kg weight loss and a palpable mass. He has had a multiphase CT, MRI with MRCP and an ultrasound-guided core biopsy. He has no jaundice, itching, fever or vomiting, and works full days. He reviewed the images with us and asked for a plain account. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
- Sun Yat-sen was born on November 12, 1866, into an ordinary farming family in Cuiheng Village. He was called Dixiang in childhood and also had the names Mingwen, Deming and Rixin; the name Yat-sen came into use while he was in Japan. [D]
- He went to a private school at nine, studied in Honolulu from the age of thirteen, and returned home at seventeen. [D]
- He began studying Western medicine at the Boji Hospital in Guangzhou in 1886 and in 1887 transferred to the College of Medicine for Chinese in Hong Kong, as one of its twelve students; his teachers included Patrick Manson. He was one of two students who passed the graduation examination in 1892 and received his diploma at the college's first graduation ceremony on July 23, 1892. [D]
- After graduating he practiced medicine in Macau, first at the Kiang Wu Hospital and then in a dispensary of his own, and then in Guangzhou, opening pharmacies that offered Chinese and Western medicines; about two years after graduating he gave up medicine for politics. [D]
- In 1894 he founded the China Revival Society in Honolulu; in 1905 he founded the Chinese Revolutionary League in Tokyo; on New Year's Day 1912 he became Provisional President of the Republic of China in Nanjing; and in January 1924 he presided over the First National Congress of the Kuomintang in Guangzhou. [D]
6 later historical claims are omitted because they describe events after the index age. See the teaching note.
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day | Two tablets by mouth every 8 hours as needed, no more than 3,000 mg a day | Oral route | 1924-05-04 | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arranged | resolved | confirmed |
R19.01 | S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis. |
| Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinoma | active | confirmed |
C23 | S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy. |
| Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitored | active | confirmed |
Z86.19 | S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis. |
Physical Exam
Vital signs recorded on 1924-05-18; see the referring visit's Vital Signs section. [S]
| System | Finding |
|---|
| General | Thin, alert, no jaundice; blood pressure 128/82, pulse 86; ECOG 1 |
| Abdomen | Firm, non-tender mass 4 cm below the right costal margin, moving with breathing; no ascites |
| Lymph nodes | No supraclavicular or umbilical nodes |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 1924-05-18 | ECOG Performance Status score | 1 | {score} | | | S |
Assessment
- Adenocarcinoma of the gallbladder invading the liver (C23). This is not a primary liver cancer. In a liver without cirrhosis the imaging criteria for hepatocellular carcinoma do not apply and tissue is needed; the biopsy shows an adenocarcinoma with a pancreatobiliary pattern, the imaging shows it arising from the gallbladder wall, and alpha-fetoprotein is normal. This is a primary gallbladder adenocarcinoma invading the liver, clinical T3 N1 M0 (stage IIIB) on imaging. Gallbladder cancer often has peritoneal spread that CT does not show, so a staging laparoscopy should come before any attempt at resection. If there is no metastatic disease, an extended cholecystectomy with resection of segments IVb and V and portal lymphadenectomy could be curative in intent; if there is, treatment is systemic: gemcitabine and cisplatin with durvalumab is the preferred first-line regimen. Genomic profiling of the biopsy now will save time if a targeted treatment becomes relevant. [S]
- Resolved hepatitis B infection (Z86.19). Resolved past infection with undetectable HBV DNA and preserved liver function (Child-Pugh A6, ALBI grade 2). It does not limit surgery or chemotherapy. The reactivation risk with gemcitabine, cisplatin and durvalumab is low to moderate; monitoring HBV DNA and ALT every 3 months, with entecavir if HBV DNA becomes detectable, is appropriate. Hepatitis C is excluded. [S]
Data reviewed: Multiphase CT of the liver with CT of the chest, abdomen and pelvis: a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, gallstones, two enlarged hepatoduodenal ligament nodes (1.6 and 1.3 cm), main portal vein and hepatic artery free, no other liver lesions, no ascites, a 6 mm calcified granuloma in the right upper lobe. MRI with MRCP: the mass arises from the gallbladder wall; no bile duct dilation; liver smooth without cirrhosis. Core biopsy: moderately differentiated adenocarcinoma, CK7 positive, CK20 and CDX2 negative. Alpha-fetoprotein 3.2 ng/mL, CA 19-9 412 U/mL, CEA 8.6 ng/mL. Albumin 3.4 g/dL, bilirubin 0.9 mg/dL, INR 1.0, creatinine 0.86 mg/dL. Hepatitis B surface antigen negative, core antibody positive, surface antibody 85 mIU/mL, HBV DNA undetectable; hepatitis C antibody negative. [S]
Plan of Treatment
- Multidisciplinary hepatobiliary tumor board review this week. [S]
- Staging laparoscopy before any resection, with biopsy of any peritoneal disease and an implanted port placed under the same anesthetic. [S]
- If there are no metastases: extended cholecystectomy with resection of liver segments IVb and V and portal lymphadenectomy, then adjuvant treatment; if there are metastases: gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 with durvalumab 1,500 mg on day 1 every 21 days for up to 8 cycles, then durvalumab every 4 weeks. [S]
- Comprehensive genomic profiling of the biopsy tissue now (HER2, mismatch repair and microsatellite status, FGFR2, IDH1, BRAF, NTRK, RET, KRAS, tumor mutational burden). [S]
- HBV DNA and ALT every 3 months during treatment and for 6 to 12 months after, with entecavir if HBV DNA becomes detectable or surface antigen reappears. [S]
- Specialist palliative care alongside treatment as soon as advanced disease is confirmed, or earlier if he wishes. [S]
- Results shared with him in full and in person, with his images, by one coordinating clinician; the same pathway and the same thresholds as for any patient. [S]
- Discussed with Dr. Huang, who sees him the same day. Mr. Sun reviewed the images and the pathology with us. We explained why a staging laparoscopy comes before any operation, what each result would mean for treatment, and that the aim of treatment would be decided by that result. He asked to hear results himself first and to decide who else is told; he agreed to the plan. He decides who receives this note. [S]
- Follow-up: Tumor board this week; staging laparoscopy in about ten days; review with Dr. Huang and the oncology team in two weeks with the result to decide treatment. [S]